Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melflufen vs Pomalidomide in RRMM (OCEAN)
NCT03151811Phase 3Terminated
- Sponsor
- Oncopeptides AB
- Start
- Jun 2017
- Primary completion
- Feb 2021
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 21
01
Overview
Phase 3, randomised, open-label trial of melphalan flufenamide in multiple myeloma (MM) (2 arms), sponsored by Oncopeptides AB. Primary endpoint: Progression Free Survival up to 43 months. Started Jun 2017; status: terminated.
02
Drugs
melphalan flufenamide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03151811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03151811.